{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:49Z","timestamp":1759017889511,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clinthera.2020.05.015","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T08:45:21Z","timestamp":1593074721000},"page":"1390-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-pill Combination Therapy of Azilsartan Medoxomil\/Chlorthalidone for Treatment of Hypertension: A Systematic Review"],"prefix":"10.1016","volume":"42","author":[{"given":"Ami","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gee-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.05.015_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.05.015_bib2","first-page":"553","article-title":"Worldwide epidemic of hypertension","volume":"22","author":"Chockalingam","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2020.05.015_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(94)91285-8","article-title":"Epidemiology of hypertension","volume":"344","author":"Whelton","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.05.015_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jash.2018.01.004","volume":"12","author":"Brook","year":"2018","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib5","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.05.015_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.05.015_bib7","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"B\u00f6hm","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.05.015_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/08037051.2015.1106750","article-title":"No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial","volume":"25","author":"Kjeldsen","year":"2016","journal-title":"Blood Press"},{"key":"10.1016\/j.clinthera.2020.05.015_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2020.05.015_bib10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib11","first-page":"1462","article-title":"2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.05.015_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjmed.2008.02.038","article-title":"Angiotensin receptor blockers: current status and future prospects","volume":"121","author":"Ram","year":"2008","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2020.05.015_bib13","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.jhh.1001352","article-title":"Angiotensin II receptor antagonists role in arterial hypertension","volume":"16","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2002","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF03261917","article-title":"Azilsartan medoxomil: a review of its use in hypertension","volume":"32","author":"Perry","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2020.05.015_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FJC.0b013e31821dcbea","article-title":"The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques","volume":"58","author":"French","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.015_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In\u00a0vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2020.05.015_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/hr.2012.8","article-title":"Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study","volume":"35","author":"Rakugi","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2020.05.015_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MJT.0b013e31824a0ed7","article-title":"Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists","volume":"21","author":"Lanier","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2020.05.015_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MBP.0000000000000042","article-title":"Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension","volume":"19","author":"Rakugi","year":"2014","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.clinthera.2020.05.015_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/erc.10.27","article-title":"Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics","volume":"8","author":"Duarte","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2020.05.015_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.1980.44","article-title":"Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders","volume":"27","author":"van Brummelen","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.05.015_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/HYPERTENSIONAHA.110.164566","article-title":"Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?","volume":"57","author":"Flack","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","article-title":"Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability","volume":"43","author":"Carter","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1345\/aph.1R618","article-title":"Azilsartan medoxomil\/chlorthalidone: a new fixed-dose combination antihypertensive","volume":"47","author":"Pierini","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2020.05.015_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2013.6","article-title":"Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril","volume":"27","author":"B\u00f6nner","year":"2013","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12872-016-0222-6","article-title":"Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry","volume":"16","author":"Gitt","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2020.05.015_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":"The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure","volume":"13","author":"Bakris","year":"2011","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2020.05.015_bib28","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.015_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/HJH.0000000000000839","article-title":"Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes","volume":"34","author":"White","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jch.12873","article-title":"Azilsartan in patients with mild to moderate hypertension using clinic and ambulatory blood pressure measurements","volume":"19","author":"Perez","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2020.05.015_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jch.12895","article-title":"The impact of azilsartan medoxomil treatment (capsule formulation) at doses ranging from 10 to 80 mg: significant, rapid reductions in clinic diastolic and systolic blood pressure","volume":"19","author":"Perez","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2020.05.015_bib34","first-page":"41","article-title":"Improvement of diurnal blood pressure variation by azilsartan","volume":"10","author":"Okamura","year":"2018","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.clinthera.2020.05.015_bib35","first-page":"618","article-title":"Effect of azilsartan on day-to-day variability in home blood pressure: a prospective multicenter clinical trial","volume":"9","author":"Miyoshi","year":"2017","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.clinthera.2020.05.015_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10557-018-6799-5","volume":"32","author":"Takahama","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2020.05.015_bib37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2017.07.022","article-title":"Azilsartan ameliorates diabetic cardiomyopathy in young db\/db mice through the modulation of ACE-2\/ANG 1-7\/Mas receptor cascade","volume":"144","author":"Sukumaran","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.015_bib38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/s41440-018-0099-0","article-title":"Azilsartan attenuates cardiac damage caused by high salt intake through the downregulation of the cardiac (pro)renin receptor and its downstream signals in spontaneously hypertensive rats","volume":"41","author":"Komaki","year":"2018","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2020.05.015_bib39","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0002-9149(85)90404-7","article-title":"Systolic hypertension in the elderly Program (SHEP): antihypertensive efficacy of chlorthalidone","volume":"56","author":"Hulley","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2020.05.015_bib40","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.05.015_bib41","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.05.015_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1751-7176.2012.00679.x","article-title":"The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans","volume":"14","author":"Lund","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2020.05.015_bib44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ajh.2010.1","article-title":"Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium","volume":"23","author":"Ernst","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","article-title":"Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate","volume":"59","author":"Peterzan","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.05.023","article-title":"Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil","volume":"125","author":"Bakris","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2020.05.015_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/HYPERTENSIONAHA.111.188284","article-title":"Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension","volume":"60","author":"Cushman","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/jch.13230","article-title":"Long-term efficacy and tolerability of azilsartan medoxomil\/chlorthalidone vs olmesartan medoxomil\/hydrochlorothiazide in chronic kidney disease","volume":"20","author":"Bakris","year":"2018","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2020.05.015_bib49","doi-asserted-by":"crossref","first-page":"13155","DOI":"10.1038\/s41598-018-31549-5","article-title":"Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC\/AHA Hypertension Guideline","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.05.015_bib50","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2020.05.015_bib51","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/heartjnl-2015-308297","article-title":"Diagnosis and management of resistant hypertension","volume":"103","author":"Sheppard","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2020.05.015_bib52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clinthera.2020.05.015_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/VHRM.S22583","article-title":"Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension","volume":"8","author":"Shuster","year":"2012","journal-title":"Vasc Health Risk Manag"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:04Z","timestamp":1758963184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0149291820302769"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-pill Combination Therapy of Azilsartan Medoxomil\/Chlorthalidone for Treatment of Hypertension: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}